(Q33824835)

29 July 2017

1 reference

title

A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection (English)

1 reference

29 July 2017

S C Piscitelli

1

1 reference

29 July 2017

N Bhat

series ordinal

2

1 reference

29 July 2017

A Pau

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

22

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

19-31

1 reference

Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection

29 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200022010-00003

Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200022010-00003

Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200022010-00003

Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study

21 January 2018

1 reference

12 December 2020

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

1 reference

12 December 2020

Supportive care during aldesleukin therapy for patients infected with human immunodeficiency virus.

1 reference

12 December 2020

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

12 December 2020

Toxicity management in patients receiving low-dose aldesleukin therapy

1 reference

12 December 2020

Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism

1 reference

12 December 2020

Fatigue in HIV-infected men receiving investigational interleukin-2.

1 reference

12 December 2020

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

12 December 2020

Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

1 reference

12 December 2020

In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients

1 reference

12 December 2020

Defective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection

1 reference

12 December 2020

Rational interleukin-2 therapy.

1 reference

12 December 2020

Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection

1 reference

12 December 2020

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

12 December 2020

Rapid cytokine release in cancer patients treated with interleukin-2

1 reference

12 December 2020

Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection

1 reference

12 December 2020

Interleukin-2 toxicity

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients

1 reference

12 December 2020

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome

1 reference

12 December 2020

Lowest dose interleukin-2 immunotherapy.

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

12 December 2020

The interleukin 2 receptor

1 reference

12 December 2020

Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease

1 reference

12 December 2020

Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

T cell growth factor receptors. Quantitation, specificity, and biological relevance

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy

1 reference

12 December 2020

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

12 December 2020

Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines

1 reference

12 December 2020

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

12 December 2020

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

12 December 2020

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

12 December 2020

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.

1 reference

12 December 2020

Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants

1 reference

12 December 2020

Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy

1 reference

12 December 2020

Regulation of virus infections by natural killer cells. A review.

1 reference

12 December 2020

Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity

1 reference

12 December 2020

10.2165/00002018-200022010-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1039401774

0 references

1 reference